Pharmacogenetics in perioperative medicine

Current Opinion in Anaesthesiology

Volumn 25, Issue 4, 2012, Pages 419-427

  Cohen, Mindy ^a   Sadhasivam, Senthilkumar ^b   Vinks, Alexander A ^b,c  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

analgesia; anesthesia; genetic; pharmacogenetics; pharmacogenomics; polymorphism

Indexed keywords

CELECOXIB; CLOPIDOGREL; CODEINE; DESFLURANE; DIAZEPAM; DRUG METABOLITE; DRUG METABOLIZING ENZYME; FENTANYL; GLUCURONOSYLTRANSFERASE 2B7; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; ISOFLURANE; KETAMINE; METHADONE; MIDAZOLAM; MORPHINE; MORPHINE 3 GLUCURONIDE; MU OPIATE RECEPTOR; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PROPOFOL; REMIFENTANIL; SEROTONIN TRANSPORTER; SEVOFLURANE; SUXAMETHONIUM; TRAMADOL; UNINDEXED DRUG;

ANALGESIC ACTIVITY; COPY NUMBER VARIATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TRANSFORMATION; ETHNICITY; GENE FREQUENCY; GENETIC VARIABILITY; HAPLOTYPE; LABOR INDUCTION; MALIGNANT HYPERTHERMIA; MEDICAL RESEARCH; MEDICINE; MUSCLE RELAXATION; OBSTETRIC ANALGESIA; PERIOPERATIVE MEDICINE; PHARMACOGENETICS; POSTCESARIAN SECTION ANALGESIA; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENERGIC BETA-ANTAGONISTS; ANESTHETICS, INHALATION; ARYL HYDROCARBON HYDROXYLASES; BENZODIAZEPINES; HUMANS; INDIVIDUALIZED MEDICINE; PERIOPERATIVE CARE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE NAUSEA AND VOMITING; PROPOFOL; RECEPTORS, OPIOID, MU;

EID: 84863786412     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3283556129     Document Type: Review

References (86)

1. Sawyer MB, Innocenti F, Das S, et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003; 73:566-574.
2. Campa D, Gioia A, Tomei A, et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83:559-566.
3. Rakvag TT, Ross JR, Sato H, et al. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008; 4:64.
4. Kolesnikov Y, Gabovits B, Levin A, et al. Combined catechol-O- methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. Anesth Analg 2011; 112:448-453.
5. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009; 146:270-275.
6. Tan EC, Lim EC, Teo YY, et al. Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for postoperative pain. Mol Pain 2009; 5:32.
7. Tateishi T, Krivoruk Y, Ueng YF, et al. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996; 82:167-172.
8. Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 1996; 24:932-939.
9. Fukuda K, Hayashida M, Ide S, et al. Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain 2009; 147:194-201.
10. Landau R, Kern C, Columb MO, et al. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008; 139:5-14.
11. Mahmoud S, Thorsell A, Sommer WH, et al. Pharmacological consequence of the A118G mu opioid receptor polymorphism on morphine- and fentanylmediated modulation of Ca(2) channels in humanized mouse sensory neurons. Anesthesiology 2011; 115:1054-1062.
12. Kosek E, Jensen KB, Lonsdorf TB, et al. Genetic variation in the serotonin transporter gene (5-HTTLPR, rs25531) influences the analgesic response to the short acting opioid remifentanil in humans. Mol Pain 2009; 5:37.
13. Benetton SA, Borges VM, Chang TK, et al. Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica 2004; 34:335-344.
14. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality. Part I. Psychosomatics 2003; 44:167-171.
15. Bunten H, Liang WJ, Pounder DJ, et al. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010; 88:383-389.
16. Bunten H, Liang WJ, Pounder D, et al. CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 2011; 16:142-144.
17. Kharasch ED, Hoffer C, Whittington D, et al. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004; 76:250-269.
18. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: Abcb1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011; 21:152-161.
19. Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin Pharmacol Ther 2006; 79:461-479.
20. Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32:447-454.
21. Hutchinson MR, Menelaou A, Foster DJ, et al. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2004; 57:287-297.
22. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91:321-326.
23. Stamer UM, Stuber F, Muders T, et al. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008; 107:926-929.
24. Wang G, Zhang H, He F, et al. Effect of the CYP2D6-10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62:927-931.
25. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105:231-238.
26. Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Investig 1992; 70:708-710.
27. Borlak J, Hermann R, Erb K, et al. A rapid and simple CYP2D6 genotyping assay: Case study with the analgetic tramadol. Metabolism 2003; 52:1439-1443.
28. Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60:636-644.
29. Gillen C, Haurand M, Kobelt DJ, et al. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedeberg Arch Pharmacol 2000; 362:116-121.
30. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010; 278:165-188.
31. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54:33-41.
32. Kirchheiner J, Meineke I, Freytag G, et al. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72:62-75.
33. Sandberg M, Yasar U, Stromberg P, et al. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002; 54:423-429.
34. Lundblad MS, Ohlsson S, Johansson P, et al. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9-3. Clin Pharmacol Ther 2006; 79:287-288.
35. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5:2429-2436.
36. Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011; 90:328-332.
37. Scott SA, Martis S, Peter I, et al. Identification of CYP2C19-4B: Pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J 2011. [Epub ahead of print]
38. Restrepo JG,Garcia-Martin E, Martinez C, et al. Polymorphic drug metabolism in anaesthesia. Curr Drug Metab 2009; 10:236-246.
39. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. Anesthesiology 2004; 101:279-283.
40. Park CS. The influence of GABAAg2 genetic polymorphism on the emergence agitation induced by sevoflurane. Korean J Anesthesiol 2008; 55:139-144.
41. Court MH, Duan SX, Hesse LM, et al. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001; 94:110-119.
42. Mo SL, Liu YH, Duan W, et al. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 2009; 10:730-753.
43. Sieghart W. Pharmacology of benzodiazepine receptors: An update. J Psychiatry Neurosci 1994; 19:24-29.
44. Inomata S, Nagashima A, Itagaki F, et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 2005; 78:647-655.
45. Qin XP, Xie HG, Wang W, et al. Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 1999; 66: 642-646.
46. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13:595-606.
47. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: Do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005; 102:543-549.
48. Liem EB, Joiner TV, Tsueda K, et al. Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads. Anesthesiology 2005; 102:509-514.
49. Swen JJ, Nijenhuis M, De Boer A, et al. Pharmacogenetics: From bench to byte - An update of guidelines. Clin Pharmacol Ther 2011; 89:662-673.
50. Yuan H, Huang Z, Yang G, et al. Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol. J Int Med Res 2008; 36:1354-1362.
51. Sofowora GG, Dishy V, Muszkat M, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73:366-371.
52. Kadiev E, Patel V, Rad P, et al. Role of pharmacogenetics in variable response to drugs: Focus on opioids. Expert Opin Drug Metab Toxicol 2008; 4:77-91.
53. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J pain 2010; 26 (Suppl 10):S16-S20.
54. Smith HS. The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain 2011; 27:824-838.
55. Gibbons CA, Blaine SM, Allanson J, et al. Genetics: Codeine metabolism. Can Fam Physician 2009; 55:164.
56. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7:257-265.
57. Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding: Fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53:33-35.
58. Madadi P, Ross C, Hayden M, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: A case-control study. Clin Pharmacol Ther 2009; 85:31-35.
59. Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: Clinical implications. Oncologist 2006; 11:126-135.
60. Neville KA, Becker ML, Goldman JL, et al. Developmental pharmacogenomics. Paediatr Anaesth 2011; 21:255-265.
61. FDA. Pharmacogenomic Biomarkers in Drug Labels. 2012. http://www. fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm 083378.htm. [Accessed 11 May 2012].
62. Nagele P, Zeugswetter B, Wiener C, et al. Influence of methylenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology 2008; 109:36-43.
63. Davis PJ, Brandom BW. The association of malignant hyperthermia and unusual disease: When you're hot you're hot or maybe not. Anesth Analg 2009; 109:1001-1003.
64. Galli L, Orrico A, Lorenzini S, et al. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. Hum Mutat 2006; 27:830.
65. Zanger UM, Klein K, Saussele T, et al. Polymorphic CYP2B6: Molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8:743-759.
66. Iohom G, Ni Chonghaile M, O'Brien JK, et al. An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. Eur J Anaesthesiol 2007; 24:912-919.
67. Oda Y, Hamaoka N, Hiroi T, et al. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001; 51:281-285.
68. Li Lin A, Shangari N, Chan TS, et al. Herbal monoterpene alcohols inhibit propofol metabolism and prolong anesthesia time. Life Sci 2006; 79:21-29.
69. Rueffert H, Thieme V, Wallenborn J, et al. Do variations in the 5-HT3A and 5-HT3B serotonin receptor genes (HTR3A and HTR3B) influence the occurrence of postoperative vomiting? Anesth Analg 2009; 109:1442-1447.
70. Ribeiro-Dasilva M, Wallace M, Glover T. The dopamine receptor 2 (DRD2) gene is associated with opioid-induced nausea and emesis. J Pain 2009; 10 (Suppl 1):S29.
71. Janicki PK, Vealey R, Liu J, et al. Genome-wide association study using pooled DNA to identify candidate markers mediating susceptibility to postoperative nausea and vomiting. Anesthesiology 2011; 115:54-64.
72. Yang W, Drewe JA, Lan NC. Cloning and characterization of the human GABAA receptor alpha 4 subunit: Identification of a unique diazepaminsensitive binding site. Eur J Pharmacol 1995; 291:319-325.
73. Iwata N, Cowley DS, Radel M, et al. Relationship between a GABAA alpha 6 Pro385Ser substitution and benzodiazepine sensitivity. Am J Psychiatry 1999; 156:1447-1449.
74. Sheets PL, Jackson JO 2nd, Waxman SG, et al. A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J Physiol 2007; 581:1019-1031.
75. Lanfear DE, Jones PG, Marsh S, et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005; 294:1526-1533.
76. Lanfear DE, Spertus JA, Mcleod HL. Beta2-adrenergic receptor genotype predicts survival: Implications and future directions. J Cardiovasc Nurs 2006; 21:474-477.
77. Wong CA, Mccarthy RJ, Blouin J, et al. Observational study of the effect of muopioid receptor genetic polymorphism on intrathecal opioid labor analgesia and postcesarean delivery analgesia. Int J Obstetr Anesth 2010; 19:246-253.
78. Landau R, Morales MA, Antonarakis SE, et al. Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor. Clin Pharmacol Ther 2005; 78:656-663.
79. Landau R, Xie HG, Dishy V, et al. beta2-Adrenergic receptor genotype and preterm delivery. Am J Obstet Gynecol 2002; 187:1294-1298.
80. Doh K, Sziller I, Vardhana S, et al. Beta2-adrenergic receptor gene polymorphisms and pregnancy outcome. J Perinat Med 2004; 32:413-417.
81. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006; 6:16-21.
82. Sadhasivam S. Unequal burden of perioperative pain and opioid related adverse effects in African-American and Caucasian children. Pediatrics 2012; 129:832-838.
83. Sadhasivam S, Krekels E, Chidambaran V, et al. Morphine clearance in children: Does race or genetics matter? Opioid Manag (in press).
84. PGRN. PGRN vision and mission statement. 2012. http://www.nigms.nih. gov/Research/FeaturedPrograms/PGRN/Background/Mission2010.htm. [Accessed 5 May 2011].
85. Jannetto PJ, Bratanow NC. Pain management in the 21st century: Utilization of pharmacogenomics and therapeutic drug monitoring. Expert Opin Drug Metab Toxicol 2011; 7:745-752.
86. Relling MV, Klein TE. CPIC: CLINICAL Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89:464-467.